The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present at the ATVB and KinMet 2018 meetings in San Francisco, CA, USA, May the 10th-12th, 2018

News detail

Return to all news & events

05/10/2018 Physiogenex to present at the ATVB and KinMet 2018 meetings in San Francisco, CA, USA, May the 10th-12th, 2018

Physiogenex will be presenting a study dealing with the effects of evolocumab, an anti-PCSK9 antibody, in the Golden Syrian hamster model.
This study will be presented by Dr. François Briand, Director of Research and Business Development, during the morning poster session on Saturday, May the 12th.

On Saturday May the 12th at 1:00pm, Dr. François Briand will also give the Berman & Levy Award Lecture during the KinMet 2018 meeting, a satellite meeting of ATVB on radiotracers kinetics and metabolism.

The lecture deals with the preclinical evaluation of drugs targeting type 2 diabetes, dyslipidemia, diabetic nephropathy and NASH.

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.